Imiquimod | Enzo Life Sciences ALX-420-039-M250 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Enzo Life Sciences

other brands :

Stressgen, BioMol, Alexis Corporation, Assay Designs, Alexis

product type :

chemical

product name :

Imiquimod

catalog :

ALX-420-039-M250

quantity :

250 mg

citations: 9

Reference
Fawzy I, Negm M, Ahmed R, Esmat G, Hamdi N, Abdelaziz A. Tamoxifen downregulates MxA expression by suppressing TLR7 expression in PBMCs of males infected with HCV. J Med Virol. 2014;86:1113-9 pubmed publisher
Hirai T, Kanda T, Sato K, Takaishi M, Nakajima K, Yamamoto M, et al. Cathepsin K is involved in development of psoriasis-like skin lesions through TLR-dependent Th17 activation. J Immunol. 2013;190:4805-11 pubmed publisher
Tayel S, Helmy A, Ahmed R, Esmat G, Hamdi N, Abdelaziz A. Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus. Arch Virol. 2013;158:1755-64 pubmed publisher
Sekine C, Moriyama Y, Koyanagi A, Koyama N, Ogata H, Okumura K, et al. Differential regulation of splenic CD8- dendritic cells and marginal zone B cells by Notch ligands. Int Immunol. 2009;21:295-301 pubmed publisher
Li V, Li W, Talcott K, Zhai A. Imiquimod as an antiangiogenic agent. J Drugs Dermatol. 2005;4:708-17 pubmed
Majewski S, Marczak M, Mlynarczyk B, Benninghoff B, Jablonska S. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol. 2005;44:14-9 pubmed
Hesling C, D Incan M, Mansard S, Franck F, Corbin Duval A, Chevenet C, et al. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol. 2004;150:761-7 pubmed
Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200 pubmed
Miller R, Gerster J, Owens M, Slade H, Tomai M. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999;21:1-14 pubmed

product information

Product ID :

ALX-420-039

Catalog Number :

ALX-420-039-M250

Product Name :

Imiquimod

Product Type :

Biochemical

Size :

250 mg

list of Pubmed id :

24615767, 23543761, 23525700, 19181931, 16302556, 15663652, 15099376, 11812998, 10411278

Product Description :

Topical immune response modifier that inhibits angiogenesis. Up-regulates IL-18 and down-regulates MMP-9 through recognition of Toll-like receptor 7 (TLR7) and subsequent activation of MyD88-dependent pathway.

ALTnames :

1-(2-Methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, R-837

Purity :

≥98% (HPLC)

Storage :

-20°C